ML20046B571
| ML20046B571 | |
| Person / Time | |
|---|---|
| Issue date: | 06/16/1993 |
| From: | Rathbun D NRC OFFICE OF CONGRESSIONAL AFFAIRS (OCA) |
| To: | Lehman R, Lieberman J, Sharp P HOUSE OF REP., HOUSE OF REP., ENERGY & COMMERCE, SENATE, ENVIRONMENT & PUBLIC WORKS |
| Shared Package | |
| ML20046B572 | List: |
| References | |
| FRN-58FR33396, RULE-PR-30, RULE-PR-32, RULE-PR-35 NUDOCS 9308050173 | |
| Download: ML20046B571 (4) | |
Text
x,-
[@ REC O
'o UNITED STATES I '~
NUCLEAR REGULATORY COMMISSION WASHINGTON. D. C. 20555 l
.p k
g j
j
+....
June 16, 1993 I
l l
i The Honorable Joseph I.
Lieberman, Chairman Subcommittee on Clean Air and Nuclear Regulation Committee on Environment and Public Works United States Senate j
Washington, D.
C.
20510
Dear Mr. Chairman:
In the near future the Nuclear Regulatory Commission (NRC) intends to publish in the Federal Reaister the enclosed proposed rule.
This proposed rule would amend the NRC's regulations in 10 CFR Parts 30, 32, and 35 to eliminate certain restrictions regarding the medical use of byproduct material.
Specifically, among other things, the proposed rule would
~
incorporate into NRC's regulations.the concept of authorized nuclear pharmacists to allow properly qualified pharmacists greater discretion to prepare radioactive drugs containing byproduct material.
Also, the proposed rule would allow physician authorized users greater discretion to prepare and use j
radioactive drugs containing byproduct material, the use of byproduct material in research involving human subjects, and the use of radiolabeled biologics containing byproduct material.
The Commission believes that the proposed rule, if adopted, would result in a small cost reduction for medical use licensees without compromising the level of protection of public health and safety against radiological hazards.
Sincerely, l
LA6-l Dennis K. Rathbun, Director Office of Congressional Affairs
Enclosure:
Federal Register Notice cc:
Senator Alan K.
Simpson 2L910g I
r e3
(
9308050173 930616
)
L PDR PR j
l 30 MISC PDR l
l
m ora
/
UNITED STATES NUCLEAR REGULATORY COMMISSION
~
g p
WASHINGTON, D. C. 20555 f
j June 16, 1993 The Honorable Philip Sharp, Chairman Subcommittee on Energy and Power Committee on Energy and Commerce United States House of Representatives Washington, D.
C.
20515
Dear Mr. Chairman:
In the near future the Nuclear Regulatory Commission (NRC) intends to publish in the Federal Reaister the enclosed proposed rule.
This proposed. rule would amend the NRC's regulations in i
10 CFR Parts 30, 32, and 35 to eliminate certain restrictions j
regarding the medical use of byproduct material.
i specifically, among other things, the proposed rule would incorporate into NRC's regulations the concept of authorized nuclear pharmacists to allow properly qualified pharmacists greater discretion to prepare radioactive drugs containing byproduct material.
Also, the proposed rule would allow l
physician authorized users greater discretion to prepare and use radioactive drugs containing byproduct material, the use of byproduct material in research involving human subjects, and the use of radiolabeled biologics containing byproduct material.
The Commission believes that the proposed rule, if adopted, would result in a small cost reduction for medical use licensees without compromising the level of protection of public health and safety against radiological hazards.
Sincerely, L
dp 4__
Dennis K. Rathbun, Director Office of Congressional Affairs
Enclosure:
Federal Register Notice cc:
Rep. Michael Bilirakis
~ ~.
_~
i
[
"'o UNITED STATES i
'q NUCLEAR REGULATORY COMMISSION
,y g
WASHINGTON. D. C. 20555 June 16, 1993 The Honorable Richard Lehman, Chairman Subcommittee on Energy and Mineral Resources Committee on Natural Resources United States House of Representatives
{
Washington, D.
C.
20515
Dear Mr. Chairman:
In the near future the Nuclear Regulatory Commission (NRC) intends to publish in the Federal Reaister the enclosed proposed rule.
This proposed rule would amend the NRC's regulations in 10 CFR Parts 30, 32, and.35 to eliminate certain restrictions regarding the medical use of byproduct material.
Specifically, among other things, the proposed rule would,
incorporate into NRC's regulations the concept of authorized nuclear pharmacists to allow properly qualified pharmacists greater discretion;to prepare radioactive drugs containing byproduct material.
Also, the proposed rule would allow i
physician authorized users greater discretion to prepare and use radioactive drugs containing byproduct material? the use of byproduct material in research involving human' subjects, and the use of radiolabeled biologics containing byprod.tet material.
i The Commission believes that the' proposed rule, if adopted, would
{
result in a small cost reduction for medical use licensees i
without compromising the level of protection of public health and safety against radiological hazards.
Sincerely, L
i,C GL b
Dennis K. Rathbun, Director Office of Congressional Affairs
Enclosure:
Federal Register Notice cc:
Rep. Barbara Vucanovich l
i
)
- 1 m.. -. +..
~.
i j
1 j.
June 16, 1993 The Honorable Richard H. Lehman, Chairman Subcommittee on Energy and Mineral _ Resources t
Committee on Natural Resources United States House of Representatives l
Washington, DC 20515
Dear Mr. Chairman:
i 3
In the near future the Nuclear Regulatory Commission (NRC) intends to publish 1
in the Federal Reaister the enclosed proposed-rule. This proposed rule would amend the NRC's regulations in 10 CFR Parts'30, 32, and 35 to eliminate certain restrictions regarding the medical use of byproduct materiat without-l f
compromising the level of protection of public health and safety against radiological hazards.
/
4
/
Specifically, among other things, the proposed rule-would incorporate into f
NRC's ragulations the concept _of authorized nuclear pharmacists to allow properiy qualified pharmacists greater discretion to prepare radip' active drugs containing byproduct material. Also, the proposed rule would all/ow physician authorized users greater discretion to. prepare and use radioactise drugs cor,tair,ing byproduct material, the use of byproduct material in /research j
involving human subjects, and the use' of radiolabeled biologics containing byproduct material.
/
7' l
The Commission believes that the proposed rule, if. adopted,/would result in a small cost reduction for medical use licensees 4~
Sincerely, i
Dennis K. Rathbun, Director l
Office of Congressional Affairs i
Enclosure.
i Federal Register Notice i
cc: Representative Barbara Vucanovich Distribution:
[TSECONG.LET]
Subj-circ-chron i
Reading Files \\PSBahadur EBeckjord, CHeltemes, BMorris, FCostanzi JTelford, SJones, ATse
- See previous conc.
Offc:RDB:CffA RDB:DRA:RES RDB:DRA:RES DD:DRA:RES D:DRA:RES DD:GIR:RES Name:ATse: 'w
- JTel ford
- SBahadur*
FCostanzi* -
BMorris*
CHeltemes*
Date:l/6/9 1/6/93 1/6/93 1/11/93 1/11/93.
1/12/93 Offc-(0CA Name:
E DRathbun Date:
93
/
/93
'l 6\\
OFFICIAL RECORD COPY i
2.
_,-,_~.._..,.__..J